A Randomized, Double-Blind, Placebo-Controlled, Study to Determine the Efficacy and Safety of 5 Dose Regimens of RO4402257 [pamapimod] in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Study to Determine the Efficacy and Safety of 5 Dose Regimens of RO4402257 [pamapimod] in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Pamapimod (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ARROW
  • Sponsors Roche
  • Most Recent Events

    • 18 Aug 2008 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 18 Aug 2008 Status change from in progress to completed according to Roche protocol registry.
    • 08 Jan 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top